Famotidine Side Effects
Famotidine is generally well-tolerated with common side effects including headache, dizziness, and constipation occurring in ≥1% of patients, but serious central nervous system reactions (confusion, delirium, hallucinations, seizures) can occur, particularly in elderly patients and those with renal impairment. 1
Common Side Effects (≥1% incidence)
Based on clinical trials of approximately 2,500 patients, the most frequent adverse reactions are 1:
- Headache
- Dizziness
- Constipation
Less Common Side Effects (<1% in clinical trials)
Gastrointestinal
- Nausea, vomiting, abdominal discomfort
- Anorexia, dry mouth
- Elevated liver enzymes 1
Neurologic/Psychiatric
- Seizures
- Hallucinations, depression, anxiety
- Decreased libido, insomnia, somnolence 1
Cardiovascular
- Palpitations 1
Other Systems
- Musculoskeletal pain, arthralgia
- Thrombocytopenia
- Pruritus, dry skin, flushing
- Tinnitus, taste disorder
- Impotence 1
Serious Adverse Reactions
Central Nervous System Toxicity (Critical Warning)
CNS adverse reactions represent the most clinically significant risk with famotidine 1. These include:
- Confusion, delirium
- Hallucinations, disorientation
- Agitation
- Seizures
- Lethargy 1
High-risk populations requiring particular vigilance 1, 2, 3:
- Elderly patients (regardless of renal function)
- Moderate renal impairment (CrCl 30-60 mL/min): 2-fold increase in drug exposure
- Severe renal impairment (CrCl <30 mL/min): ≥5-fold increase in drug exposure
- Neurosurgical patients: CSF/plasma ratio 4 times higher than non-neurosurgical patients (0.41-0.46 vs 0.12) 3
The mechanism involves excessive CNS accumulation due to reduced renal clearance, with documented toxic CSF concentrations of 160-249 ng/mL in symptomatic patients versus 47-85 ng/mL in asymptomatic patients with renal failure 3.
Postmarketing Serious Reactions
Life-threatening complications reported include 1:
- Cardiovascular: Arrhythmia, AV block, prolonged QT interval
- Hepatic: Cholestatic jaundice, hepatitis
- Hematologic: Agranulocytosis, pancytopenia, leukopenia
- Hypersensitivity: Anaphylaxis, angioedema
- Musculoskeletal: Rhabdomyolysis
- Respiratory: Interstitial pneumonia
- Dermatologic: Toxic epidermal necrolysis/Stevens-Johnson syndrome
Pediatric-Specific Considerations
In infants and children, famotidine may cause 4:
- Agitation or irritability (most common, including head-rubbing behavior in infants)
- Somnolence
- Anorexia
- Headache
- Vomiting
These effects occurred in 11 of 35 infants studied, with agitation/irritability being the predominant concern 4.
Cutaneous Manifestations
Recent case series identified acral macular skin lesions in COVID-19 patients receiving famotidine, which resolved completely upon drug discontinuation 5. While rare, this represents an emerging recognition of dermatologic reactions.
Clinical Pitfalls to Avoid
Failure to dose-adjust in renal impairment: This is the single most important error leading to CNS toxicity. Mandatory dose reduction when CrCl <60 mL/min 1.
Overlooking age as independent risk factor: Elderly patients are at increased CNS toxicity risk even with normal renal function 2.
Misattributing CNS symptoms: In critically ill or postoperative patients, confusion/agitation may be incorrectly attributed to underlying illness rather than famotidine toxicity 3.
Inadequate monitoring in high-risk groups: Neurosurgical patients require heightened surveillance due to dramatically increased CNS penetration 3.
Comparative Safety Profile
Famotidine demonstrates an excellent overall safety profile with only 0.43% of patients experiencing side effects in post-marketing surveillance 6. The drug does not interact with cytochrome P-450, avoiding the drug-drug interactions seen with cimetidine 6. However, this favorable profile applies primarily to patients with normal renal function and appropriate dosing.